Overview

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2023-08-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the single dose pharmacokinetics (PK) and evaluate the safety and tolerability of subcutaneous administration of rilpivirine (RPV) long-acting (LA) extended release suspensions in different conditions in healthy adult participants.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Rilpivirine